Transferability and Relevance of Cost-Effectiveness Data Between Countries

Go Back

Although the number of countries requiring an economic dossier as part of the submission dossier for public reimbursement of new drugs is growing, the pharmaceutical industry cannot conduct economic evaluations in every potential market. However, national decision makers require country-specific or region-specific data or relevant estimates on health care costs and patient outcomes. More and more, they are only willing to accept foreign or international data when transferable to their own decision-making context. However, little guidance exists on how to do this. This course starts with a discussion of factors that make economic data more difficult to transfer from one country to another than clinical data, and will focus on the report of the ISPOR Good Practices on Economic Data Transfer...